問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

National Taiwan University Hospital

List

1738Cases

2025-02-01 - 2032-12-31

Phase III

Active
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor and Letrozole in Patients With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

  • Condition/Disease

    Breast Cancer

  • Test Drug

    lozenges

Participate Sites
6Sites

Recruiting6Sites

2020-11-01 - 2027-12-31

Phase III

Active
A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

  • Condition/Disease

    Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

  • Test Drug

    GDC-9545letrozolePalbociclib

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting3Sites

2020-12-01 - 2025-12-31

Phase II

Active
A Phase II, Randomized,Open-Label, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Compared with physician's choice of endocrine monotherapy in Patients with Previously treated Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer.

  • Condition/Disease

    Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

  • Test Drug

    GDC-9545 Anastrozole Fulvestrant Letrozole Exemestane

Participate Sites
5Sites

Recruiting5Sites

2021-06-01 - 2031-12-24

Phase III

Active
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ATEZOLIZUMAB OR PLACEBO AND TRASTUZUMAB EMTANSINE FOR HER2-POSITIVE BREAST CANCER AT HIGH RISK OF RECURRENCE FOLLOWING PREOPERATIVE THERAPY　

  • Condition/Disease

    主要療效目的 本試驗的主要療效目的乃是根據下列指標，評估 atezolizumab 併用trastuzumab emtansine 相較於安慰劑加上 trastuzumab emtansine 的療效： IDFS，定義為自隨機分配

  • Test Drug

    注射液劑

Participate Sites
6Sites

Recruiting6Sites

2022-06-01 - 2032-12-31

Phase III

Active
A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Giredestrant in Combination With Phesgo Versus Phesgo After Induction Therapy With Phesgo + Taxane in Patients With Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally-Advanced or Metastatic Breast Cancer

  • Condition/Disease

    Locally Advanced or Metastatic Breast Cancer

  • Test Drug

    GiredestrantPhesgo (1200/600 mg)Phesgo (600/600 mg)

Participate Sites
5Sites

Recruiting5Sites

2023-09-01 - 2033-12-31

Phase III

Active
AN OPEN-LABEL, MULTICENTER EXTENSION STUDY IN PATIENTS PREVIOUSLY ENROLLED IN A GENENTECH AND/OR F. HOFFMANN-LA ROCHE LTD SPONSORED STUDY

  • Condition/Disease

    Prostate Cancer (母試驗CO39303適應症)

  • Test Drug

    Ipatasertib Abiraterone acetate

Participate Sites
4Sites

Recruiting2Sites

Terminated2Sites

2023-09-01 - 2027-12-31

Phase III

Active
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

  • Condition/Disease

    Carcinoma, Hepatocellular

  • Test Drug

    AtezolizumabBevacizumabTiragolumab

Participate Sites
5Sites

Recruiting5Sites

2023-03-01 - 2027-12-31

Others

Active
A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

  • Condition/Disease

    Metastatic Colorectal Cancer

  • Test Drug

    AtezolizumabTiragolumabInavolisibBevacizumabRO7435846(GDC-6036)CetuximabFluorouracilfolinic acid(Calcium Folinate)OxaliplatinIrinotecan

Participate Sites
3Sites

Not yet recruiting3Sites

2020-09-01 - 2027-06-30

Phase III

Active
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy

  • Condition/Disease

    Esophageal Squamous Cell Carcinoma

  • Test Drug

    AtezolizumabTiragolumab

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2020-09-01 - 2026-12-31

Phase III

Active
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Patients With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma

  • Condition/Disease

    Esophageal Squamous Cell Carcinoma

  • Test Drug

    Tiragolumab ；Atezolizumab

Participate Sites
4Sites

Recruiting4Sites

1 2 3 4 5 174
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB